Clinical trialPhase 1Completed
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 19 July 2021
- Ended
- 15 June 2023
- Enrollment
- 25 participants
- Sites
- 9
- Primary outcomes
- Frequency of TEAEs (Treatment-emergent adverse events); Number of participants with DTLs (dose-limiting toxicities); Number of subjects with 1 or more TEAEs leading to dose modifications; Number of subjects with grade ≥ 3 TEAEs; Percentage of subjects with grade ≥ 3 TEAEs
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 29 June 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.